Clark et al., 1993 - Google Patents
Respiratory arrests in young asthmatics on salmeterolClark et al., 1993
View PDF- Document ID
- 16308983557109392773
- Author
- Clark C
- Ferguson A
- Siddorn J
- Publication year
- Publication venue
- Respiratory medicine
External Links
Snippet
We report the case histories of three young asthmatics each of whom has had a recent episode of respiratory arrest. All three occurred between 1 and 4 weeks after starting on salmeterol, a new long acting inhaled b-agonist. None has previously suffered a respiratory …
- 208000006673 Asthma 0 title abstract description 23
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S514/00—Drug, bio-affecting and body treating compositions
- Y10S514/826—Asthma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Verberne et al. | Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma | |
| EP1174139B1 (en) | Use of mometasone furoate for treating airway passage and lung diseases | |
| Corren et al. | Nasal beclomethasone prevents the seasonal increase in bronchial responsiveness in patients with allergic rhinitis and asthma | |
| US6365581B1 (en) | Use of mometasone furoate for treating airway passage and lung diseases | |
| Politiek et al. | Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction | |
| König et al. | The preventive effect and duration of action of nedocromil sodium and cromolyn sodium on exercise-induced asthma (EIA) in adults | |
| Clark et al. | Respiratory arrests in young asthmatics on salmeterol | |
| EP1429712B1 (en) | Method for treating bronchial constriction and bronchospasm | |
| Bensch et al. | Once-daily evening administration of mometasone furoate in asthma treatment initiation | |
| Schroeckenstein et al. | Twelve-hour bronchodilation in asthma with a single aerosol dose of the anticholinergic compound glycopyrrolate | |
| Slavin et al. | Multicenter study of flunisolide aerosol in adult patients with steroid-dependent asthma | |
| AU2002323191A1 (en) | Method for treating bronchial constriction and bronchospasm | |
| Barnes et al. | Use of a fixed combination beta 2-agonist and steroid dry powder inhaler in asthma. | |
| US6100244A (en) | Method for treating respiratory distress by sublingual administration of DNA | |
| Gibson et al. | Drug delivery in asthma: a comparison of spacers with a jet nebuliser | |
| Baki et al. | Short‐term effects of budesonide, nedocromil sodium and salmeterol on bronchial hyperresponsiveness in childhood asthma | |
| Bousquet et al. | Comparison of salmeterol with disodium cromoglycate in the treatment of adult asthma | |
| Meltzer et al. | Once-daily mometasone furoate administered by dry powder inhaler for the treatment of children with persistent asthma | |
| Volcheck et al. | Anti-inflammatory drugs for controlling asthma: Tips on what to use and when | |
| Sveum | Childhood asthma: balancing efficacy and adherence for optimum management | |
| Ramsay et al. | Bronchoconstriction due to 8‐methoxypsoralen | |
| Saxegaard et al. | Adverse reactions: Safety of the long‐acting β‐agonist salmeterol in patients with severe bronchial obstruction | |
| WOOLCOCK | Strategies for the management of asthma | |
| Phanichyakarn et al. | Inhaled budesonide aerosols in treatment of childhood asthma. | |
| Reynolds et al. | 58 Airways hyperreactivity to bradykinin (BK) and methacholine (Mch): Differential effects of inhaled fluticasone |